scholarly journals Consolidation Chemotherapy May Improve Pathological Complete Response For Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy: Evidence From Real-World Data

2020 ◽  
Vol 108 (3) ◽  
pp. e640-e641
Author(s):  
J. Cui ◽  
X. Dou ◽  
Y. Sun ◽  
J. Yue
2020 ◽  
Author(s):  
Zhiwei Zhai ◽  
Kunning Zhang ◽  
Chen Wang ◽  
Jiagang Han ◽  
Tian Zhang ◽  
...  

Abstract Objective To compare the safety and efficacy between neoadjuvant concurrent chemoradiotherapy (CRT) and total neoadjuvant chemoradiotherapy (TNT) in patients with locally advanced rectal cancer. Methods Patients with cT3/T4 or TxN+M0 rectal cancer were randomized to receive CRT/TNT. In CRT group, we planned pelvic radiotherapy (50.0Gy in 25 fractions) with two cycles of concurrent CAPOX followed by total mesorectal excision (TME). In TNT group, 3 cycles of CAPOX were administered 2 weeks after the completion of CRT before TME. The primary endpoints of my study were pathological complete response (pCR) rates in the two cohorts. Results A total of 197 patients were included in our study. Eighty-one patients received CRT while one hundred and sixteen patients received TNT (consolidation chemotherapy). Nine patients did not undergo surgery because of the distant metastases (1 patient (1.2%) in CRT group, 2 patients (1.7%) in TNT group) or clinical complete response (cCR) (2 patients in CRT group, 4 patients in TNT group). The rate of pathological complete response in TNT was significantly higher than the rate in CRT (32.7% vs12.8%, P =0.002). No grade 4 or serious adverse events were observed. There was no statistically significant difference in the grade 3 acute toxicities of neoadjuvant treatment and surgical complications between the two groups (all P >0.05). Conclusions Our data suggests that total neoadjuvant chemoradiotherapy (consolidation chemotherapy) is effective and safe for patients with locally advanced rectal cancer and is associated with high rates of pathological complete response. The long-term follow-up and survival outcomes for patients are necessary to be evaluated in future prospective randomized trial.


2021 ◽  
Vol 28 (1) ◽  
pp. 283-293
Author(s):  
Zhiwei Zhai ◽  
Kunning Zhang ◽  
Chen Wang ◽  
Tian Zhang ◽  
Lixia Wang ◽  
...  

Background and Objectives: the total neoadjuvant chemoradiotherapy (TNT) includes different strategies, but the most appropriate model remains uncertain. The purpose of this retrospectively study was to evaluate the safety and pathological response in the consolidation chemotherapy model. Methods: patients with cT3/T4 or TxN + M0 rectal cancer that were receiving neoadjuvant chemoradiotherapy (CRT) (50 Gy with oral capecitabine)/TNT (CRT followed by three cycles of CAPOX) during September 2017 to September 2019 in our department were included. All of the patients were recommended to receive radical surgery. Results: a total of 197 patients were included. Eighty-one patients received CRT, while one hundred and sixteen patients received TNT. Nine patients did not undergo surgery because of the distant metastases (one patient (1.2%) in CRT group, two patients (1.7%) in TNT group) or a refusal of resection (two patients in CRT group, four patients in TNT group). The pathological complete response (pCR) rate was 32.7% in TNT compared with 12.8% in CRT (p = 0.002). There was no statistically significant difference in grade 3 acute toxicities of neoadjuvant treatment and surgical complications between the two groups. Conclusions: the consolidation chemotherapy model is safe for patients with locally advanced rectal cancer and it has a high pCR rate. The long-term follow-up is necessary to be evaluated in a future prospective, randomized trial.


2020 ◽  
Author(s):  
Chun-Ming Huang ◽  
Ming-Yii Huang ◽  
Ching-Wen Huang ◽  
Hsiang-Lin Tsai ◽  
Wei-Chih Su ◽  
...  

Abstract BACKGROUND For patients with locally advanced rectal cancer (LARC), achieving pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) results in best prognosis. So far, no reliable prediction model has been available. We aim to evaluate the performance of an artificial neural network (ANN) model in the prediction of pCR in patients with LARC. METHODS Predictive accuracy was compared between the ANN, k-earest neighbor (KNN), support vector machines (SVM), naïve Bayes classifier (NBC), and multiple logistic regression (MLR) models. RESULTS A total of 236 patients with LARC were used to compare the forecasting models. We trained the model with an estimation data set, and evaluated model performance with a validation data set. The ANN model significantly outperformed the KNN, SVM, NBC, and MLR models in predicting pCR. Our results revealed that post-CRT carcinoembryonic antigen was the most influential predictor of pCR, followed by intervals between CRT and surgery, chemotherapy regimens, clinical nodal stage, and clinical tumor stage. CONCLUSIONS Compared with conventional prediction models, the ANN model was more accurate in the prediction of pCR. The predictors of pCR can be used to identify which patients with LARC can benefit from watch-and-wait approaches.


Sign in / Sign up

Export Citation Format

Share Document